Browsing by author "Marsden,"
Now showing items 1-20 of 112
-
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; et al. (2017-03)Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ... -
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; et al. (MASSACHUSETTS MEDICAL SOC, 2017-11-09)BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ... -
A genomic atlas of human adrenal and gonad development.
Del Valle, I; Buonocore, F; Duncan, AJ; Lin, L; Barenco, M; et al. (2017-04-07)Background In humans, the adrenal glands and gonads undergo distinct biological events between 6-10 weeks post conception (wpc), such as testis determination, the onset of steroidogenesis and primordial germ cell development. ... -
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Prat, A; Lluch, A; Turnbull, AK; Dunbier, AK; Calvo, L; et al. (2017-06)Purpose: Hormone receptor-positive (HR + ) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified. Experimental Design: ... -
A Specific Distress Cutoff Score Shortly After Breast Cancer Diagnosis.
Ploos van Amstel, FK; Tol, J; Sessink, KH; van der Graaf, WTA; Prins, JB; et al. (2017-05)Background High levels of distress are expected shortly after the diagnosis breast cancer. The Distress Thermometer (DT) is commonly used to screen for distress, using a cutoff score of 4 or 5; however, this score might ... -
Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols
Ferrari, A; Trama, A; De Paoli, A; Bergeron, C; Merks, JHM; et al. (2017-06) -
Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer-Is There Room for Improvement?
Smyth, EC; Cunningham, D (2018-01) -
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; et al. (2017-05)Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, ... -
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; et al. (2017-03)Purpose Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, ... -
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Kasper, B; Baumgarten, C; Garcia, J; Bonvalot, S; Haas, R; et al. (2017-10)Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based ... -
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ... -
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Glynne-Jones, R; Sebag-Montefiore, D; Meadows, HM; Cunningham, D; Begum, R; et al. (2017-03)Background Guidelines for anal cancer recommend assessment of response at 6-12 weeks after starting treatment. Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after ... -
Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl, A; Cunningham, D; Chau, I (2017-09)After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery ... -
Bilateral mammoplasty for cancer: Surgical, oncological and patient-reported outcomes.
Di Micco, R; O'Connell, RL; Barry, PA; Roche, N; MacNeill, FA; et al. (2017-01)Introduction Bilateral mammoplasty (BM) can optimise oncological safety and aesthetic outcomes in women with large or ptotic breasts whose tumour to breast volume ratio or tumour location pose a challenge to standard ... -
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini, G; Kiermaier, A; Bianchi, GV; Im, Y-H; Pienkowski, T; et al. (2017-02-09)Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab ... -
Caelyx-induced unilateral erythrodysesthaesia secondary to venous thromboembolism.
Merika, EE; Gore, M; Fearfield, LA (2017-06) -
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; et al. (2017-06)Background Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ... -
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Gleeson, M; Counsell, N; Cunningham, D; Chadwick, N; Lawrie, A; et al. (2017-10)Background Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse for patients treated within the UK NCRI phase III ... -
Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Chau, I (2017-10)Gastrointestinal (GI) cancers are among the most deadly malignancies. Although serial incremental survival benefits have been made with cytotoxic chemotherapy with metastatic disease, a plateau of achievement has been ...